CUTISS AG

This week we’re looking forward to joining the ETRS 2026 Annual Meeting, which we’re also proud to sponsor.   Organised by the ETRS European Tissue Repair Society, this year’s meeting will bring together researchers, clinicians and industry partners to exchange advances in tissue repair, wound healing, bioengineering and regenerative medicine under the theme “New Strategies for Improved Wound Healing”.   Vincent Ronfard, Chief Innovation Officer, will be representing the company. On Wednesday we will give a company presentation on personalized skin, as part of the programme following the opening session on 3D bioprinting, biomaterials and bioengineering.   We look forward to connecting with the tissue repair and wound healing community and sharing more about our work to advance personalized, bio-engineered skin tissue therapy.   Come and meet us in Rouen!   #ETRS2026 #RegenerativeMedicine #TissueEngineering #WoundHealing

We're hiring! Are you our next candidate for following open positions? Let's shape the tissue therapeutics revolution together! https://lnkd.in/dYbzBPyh https://lnkd.in/dZyBgiGR https://lnkd.in/dk7fddm4

CUTISS has announced the election of Achim von Leoprechting as Chairman of its Board of Directors, as the company prepares for the next phase of growth.   Dr. von Leoprechting brings more than 25 years of international leadership experience across life sciences, diagnostics, medical device markets and laboratory automation, with a strong track record in scaling global operations. He most recently served as CEO of Tecan.   He succeeds Prof. Dr. med. Martin Meuli, co-founder of CUTISS, who has chaired the Board since the company’s foundation in 2017 and supported its development from a university spin-off into a late-stage clinical company. Prof. Meuli remains a member of the Board.   This Board transition comes as CUTISS continues to advance denovoSkin™, its personalized, bioengineered skin tissue therapy, and prepares for its upcoming milestones.   Read the full announcement: https://lnkd.in/eKS7G5Bi

CUTISS has been granted a new U.S. patent. It covers automated methods and systems for producing skin grafts, including the separation of skin layers and the isolation of key cell types from a skin biopsy. The patented invention relates to a broader automated workflow for skin graft production, in which a skin biopsy may be separated into dermis and epidermis, fibroblasts and keratinocytes isolated and expanded, and a skin graft formed under automated control. According to the patent, this approach is intended to support a more controlled and efficient manufacturing process. This new patent further strengthens our intellectual property portfolio and supports the broader strategy to advance standardized and scalable manufacturing for personalized skin tissue therapy. U.S. Patent No. 12,599,401 B2 – titled “Methods and systems for producing skin grafts” – granted on 14 April 2026 and assigned to CUTISS AG. #innovation #regenerativemedicine #tissueengineering

We're pleased to attend the 2026 Cell & Gene Meeting on the Mediterranean in Rome this week. This event - organized by the Alliance for Regenerative Medicine - is a leading European gathering for the ATMP community, bringing together companies, investors, research institutions and other stakeholders across cell therapy, gene therapy, tissue engineering, and regenerative medicine.   On Day 2, our CEO Daniela Marino will give a company presentation as part of the conference program – make sure to come by and listen!   We look forward to presenting our work in personalized skin regenerative medicine, including the continued advancement of denovoSkin™, our personalized, bio-engineered skin graft currently in late-stage clinical development in Switzerland and the European Union.   If you're attending in Rome, we would be glad to connect.   #CGMed26 #CellandGeneTherapy #CellTherapy #AdvancedTherapies #RegenerativeMedicine #Innovation 

Thank you to the organisers of the HealthCare Investors Meeting 2026, held at the Genolier Innovation Hub, for bringing together investors, analysts and innovative Swiss healthcare companies.   It was a real pleasure for us to be part of the program alongside a select handful of other promising and well-established Swiss biotechs!   This was an opportunity for us to present the company, its trajectory, and innovation in tissue engineering, as well as to highlight the strong potential of denovoSkin™, our personalized, bio-engineered skin graft for the treatment of severe skin defects and injuries.   Many thanks to Vincent Ronfard and Andreea Iordan for their participation and representation of CUTISS amongst the investment community!   AGEFI, Nouvelle Agence Économique et Financière schweizeraktien.net AG #Healthcare #Biotech #Techbio #Innovation #RegenerativeMedicine #Swisstech

𝐍𝐞𝐰 𝐩𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐫𝐞𝐩𝐨𝐫𝐭𝐬 𝐏𝐎𝐒𝐈𝐓𝐈𝐕𝐄 1-𝐲𝐞𝐚𝐫 𝐏𝐡𝐚𝐬𝐞 𝐈𝐈 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐨𝐫 𝐝𝐞𝐧𝐨𝐯𝐨𝐒𝐤𝐢𝐧™ 𝐢𝐧 𝐫𝐞𝐜𝐨𝐧𝐬𝐭𝐫𝐮𝐜𝐭𝐢𝐯𝐞 𝐬𝐮𝐫𝐠𝐞𝐫𝐲 A new peer-reviewed publication in the Journal of Tissue Engineering reports 1-year results for denovoSkin™ in reconstructive surgery.    The paper presents findings from a prospective, randomized, intra-patient controlled, multicenter Phase II clinical trial comparing denovoSkin™ with autologous split-thickness skin grafts (STSG) in 23 patients with full-thickness skin defects requiring planned elective reconstruction in patients of all ages. According to the publication, denovoSkin™ demonstrated significantly better scar quality than STSG at 3 months, with benefits maintained at 12 months. Elasticity parameters also consistently favored denovoSkin™, and significant donor site sparing was also demonstrated. The authors conclude that denovoSkin™ is a safe and effective treatment for full-thickness skin defects and provides favorable skin quality over 12 months. This publication adds to the growing body of clinical evidence supporting denovoSkin™ as a personalized, bio-engineered dermo-epidermal skin graft for the treatment of acute and elective full-thickness skin defects. We thank the patients, investigators, and clinical teams involved in this multicenter study for their important contribution to advancing innovation in reconstructive surgery.   📷 Image below shows denovoSkin™ versus autologous split thickness skin grafts (STSG) Daniela Marino Kathi Mujynya Vincent Ronfard Esther Middelkoop #ReconstructiveSurgery #RegenerativeMedicine #TissueEngineering #ClinicalResearch

We’re pleased to share that CUTISS has been granted a new U.S. patent.   This patent covers a disposable system and method for preparing compressed hydrogels for tissue engineering applications - U.S. Patent No. 12,564,662 B2, titled “Disposable system and method for preparing a compressed hydrogel”.   The patented invention relates to a core part of the tissue engineering process and supports the preparation of compressed hydrogels in a fully disposable format, with all its associated advantages.   It’s another important step in strengthening our innovation platform and intellectual property portfolio as we continue advancing denovoSkin™, our personalized, bio-engineered skin graft currently in late-stage clinical development in Switzerland and the European Union.   We continue to expand the technological foundations supporting the future of personalized skin tissue therapy 🚀   #Patent #Biotech #Techbio #RegenerativeMedicine #TissueEngineering

New publication on compassionate use of denovoSkin™ in pediatric reconstructive burn surgery   A new peer-reviewed report in the Journal of Burn Care & Research describes the U.S. compassionate use of denovoSkin™ in a pediatric patient with extensive burn injuries, treated at Massachusetts General Hospital (Boston).   For children with severe burns, reconstruction is not just about wound closure – it’s also about supporting mobility, growth, and long-term quality of life. In this case, denovoSkin™ was used in reconstructive procedures including contracture release and treatment of unstable scars and non-healed wounds.   As the authors note, the development of an autologous, full-thickness skin replacement has long been considered the “holy grail” in the treatment of severe skin loss. The publication reports high engraftment rates (95%), durable healed skin, and positive handling characteristics, further documenting the potential of personalized bio-engineered skin in complex burn reconstruction.   This report follows the first U.S. compassionate use announced in 2024 and the abstract presented in 2025, providing additional clinical detail.   In parallel, CUTISS continues to advance denovoSkin™ in an ongoing Phase 3 clinical trial in the EU and Switzerland for patients with severe skin burns.   We thank the surgical and clinical teams at Mass General Hospital, particularly Rob Sheridan, jeremy goverman and Matthew David Supple, for their continued collaboration and commitment to improving care for burn patients.   Daniela Marino Kathi Mujynya Vincent Ronfard Esther Middelkoop Luc Teot American Burn Association #BurnCare #RegenerativeMedicine #denovoSkin #TissueEngineering #TechBio  

Yesterday we celebrated the 9th BIRTHDAY of CUTISS!    Our amazing team was able to mark this milestone in a particularly meaningful way, together with our medical trainers and many of the clinical investigators and their teams involved in our ongoing Phase 3 trial who travelled to Zurich from 7 different EU countries for 2 days of workshops, networking and discussions.   Our progress is the result of a shared effort between CUTISS' team, surgeons, clinical teams, researchers, partners (including Tecan and Rode Kruis Ziekenhuis) and patients. Their trust and dedication honor us and give us an amazing motivation to keep pushing the boundaries in skin surgery.   As our Phase 3 study of denovoSkin™ and our automation program continue, we remain focused on developing a personalized, scalable and accessible skin tissue therapy that can significantly improve outcomes for patients with severe skin injuries and reduce the burden of today’s standard treatments.   We have our goals in sight, and we remain committed to make our therapy available to as many patients, as soon as possible #gogogo   Kathi Mujynya Vincent Ronfard Esther Middelkoop Luc Teot Martin Meuli